

Figure. [A, B] Prevalence of non-alcoholic fatty liver disease (NAFLD) determined by [A] the Fatty Liver Index (FLI) or [B] the Lipid Accumulation Product (LAP). Categories of nutritional status were defined according to the body mass index as: <18.5 kg/m^2 underweight, 18.5-24.9 kg/m^2 normal weight, 25.0-29.9 kg/m^2 overweight, 30.0-39.9 kg/m^2 obesity, and >39.9 kg/m^2 morbid obesity. [C, D] Association between physical activity levels and the presence of NAFLD by [C] FLI, or [D] LAP. OR [95% CI], odds ratio [95% confidence intervals].

https://doi.org/10.1016/j.aohep.2023.101051

OP-3 CLINICAL PRESENTATION AND CAUSATIVE AGENTS OF IDIOSYNCRATIC DRUG-INDUCED LIVER INJURY IN URUGUAY: FIRST DECADE OF EXPERIENCE.

Nelia Hernandez[1], Daniela Chiodi[1], Adriana Sanchez[1], Laura Reyes[2], Ximena Pazos[1], María di Pace[3], Carla Bianchi[4], Yessica Pontet[1], Silvia Lissman[5], Carmen Pollio[6], Lucía Secondo[1], Natalie Nabon[7], Ana Britos[8], Rossana Gaibisso[9], Martín Oricchio[1], Esteban Delgue[10], Fernando Bessone[11], Raúl Andrade[12], María Isabel Lucena[12]

[1] *Gastroenterology Clinic, Clinicas Hospital, University of the Republic, Montevideo, Uruguay*
[2] *Salto Medical Center, Salto, Uruguay*
[3] *Catholic Circle of Workers of Uruguay, Montevideo, Uruguay*
[4] *Mautone Sanatory, Maldonado, Uruguay*
[5] *Personalized Medicine, Montevideo, Uruguay*
[6] *Gastroenterology Department, Hospital Maciel, Montevideo, Uruguay*
[7] *Evangelical Hospital, Montevideo, Uruguay*
[8] *Tacuarembó Medical Corporation, Tacuarembó, Uruguay*
[9] *Uruguayan Medical Doctor, Montevideo, Uruguay*
[10] *Salto Regional Hospital, Salto, Uruguay*
[11] *Gastroenterology Service, Centenary Hospital, National University of Rosario, Rosario, Argentina*
[12] *Digestive System CMU, Clinical Pharmacology Service, Institute of Biomedical Research Institute of Malaga and Nanomedicine Platform-IBIMA. BIONAND Platform, Virgen de la Victoria University Hospital, University of Malaga, CIBERehd. Malaga, Spain*

Introduction and Objectives: Drug-induced liver injury (DILI), usually considered rare, represents a unique challenge. The creation of DILI registries has improved epidemiological understanding and enhanced awareness, which in the absence of specific biomarkers, is essential for a more accurate diagnosis. This study aimed to present a complete analysis of 147 Uruguayan cases with DILI enrolled in the LATINDILI Registry over ten years.

Materials and Methods: Uruguayan patients enrolled in the LATINDILI registry during the last decade were analyzed regarding latency, pattern, severity, evolution, and type of drugs incriminated. Baseline characteristics were described using mean, median, and percentages.

Results: Out of 158 episodes presenting suspected DILI, eleven were excluded for alternative diagnoses or insufficient data, and 147 were finally enrolled into the registry from 2011 to 2021. The mean age was 53 years and 60% were females. Jaundice was present in 55% of the cases; the mean latency was 75 days (1-720). Total bilirubin ranged from 0.19 to 33 mg/dl (mean 4.7), ALT from 32 to 6000 UI/L (mean 630), and AP was between 60 and 3327 UI/L with a median of 520. The hepatocellular injury was the most frequent pattern (58%), and anti-infectives were the most common causative drug class (28%), followed by antineoplastic agents (16%). Amoxicillin clavulanate was the most frequent drug across all patterns of injury. Hospital admission was seen in 51% and complete recovery before one year of follow-up in 73% (10% lost of follow-up). Table 1 describes the demographics, clinical and laboratory parameters according to the type of damage.

Conclusions: This prospective series is the first approximation of the epidemiology of DILI in Uruguay. Beyond its contribution to the LATINDILI registry, it is a priceless tool to identify/highlight local risk factors, causative drugs, and clinical signatures and can impact fostering DILI recognition.

Table 1: Demographics, clinical and laboratory parameters of the 147 cases of idiosyncratic liver injury according to the type of damage.

variable	Type of liver damage Hepatocellular (N=86)	Cholestatic (N= 41)	Mixed (N=20)
Mean age (range), y	47 (17-89)	65,2 (27-86)	51,5 (18-88)
Female, n (%)	52 (60)	26 (64,2)	10 (50%)
Jaundice, n (%)	41 (47,6)	22 (53,6)	12 (60%)
Hospital admission, n (%)	40 (46,5)	22 (53,6)	13 (65%)
Mean duration of treatment days (95% CI)	81,4 (53,2-109,7)	77,7 (42,8-112,6)	42,8 (41,1-44,5)
Mean latency, days (95% CI)	82,1 (53,9-108,5)	77,2 (45,2-109,1)	45,8 (44,1-47,5)
Total bilirrubin (mg/dl), mean value (range)	4,4 (0,19-33)	5 (0,22-15,7)	5,4 (0,26-29)
ALT (xULN), mean value (range)	24 (3,2-200,0)	4,37 (0,9-12,9)	9,6 (2,8-23,5)
AP (ULN), mean value (range)	1,45 (0,4-4,1)	4,6 (1,3-13,6)	2,7 (1-5,8)
Recovery, days (95% CI)	76,9 (68,9-103,2)	198,7 (103-294,5)	93,9 (92,2-95,7)
Positive rechallenge, n (%)	9 (10,4)	2 (4,7)	2 (10%)
Severe, n(%)	12 (13,9)	0	0
Death	1 (1,17)*	0	0
Drug with ≥5 cases	amoxicillin clavulanate (8), diclofenac (6)	amoxicillin clavulanate (13) ibuprofeno (5), metildopa (5)	amoxicillin clavulanate (5)

Total bilirubin (N<1.0 mg/dl); ALT, alanine transaminase; AP, alkaline phosphatase; ULN, upper limit of normal. Death occurred after positive rechallenge. Laboratory values are those at presentation.

https://doi.org/10.1016/j.aohep.2023.101052

OP-4 IMPLEMENTATION OF A RE-LINKAGE TO CARE STRATEGY IN PATIENTS WITH CHRONIC HEPATITIS C WHO WERE LOST TO FOLLOW-UP IN LATIN AMERICA

Manuel Mendizabal[1], Marcos Thompson[1], Esteban Gonzalez-Ballerga[2], Margarita Anders[3], Graciela E Castro-Narro[4], Mario G Pessoa[5], Hugo Cheinquer[6], Gabriel Mezzano[7], Ana Palazzo[8], Ezequiel Ridruejo[9], Valeria Descalzi[10],

Jose A Velarde-Ruiz Velasco[11], Sebastian Marciano[12], Linda Muñoz[13], Maria I Schinoni[14], Jaime Poniachik[15], Rosalía Perazzo[16], Eira Cerda[17], Francisco Fuster[18], Adriana Varon[19], Sandro Ruiz García[20], Alejandro Soza[21], Cecilia Cabrera[22], Andres J Gomez-Aldana[23], Flor de María Beltrán[24], Solange Gerona[25], Daniel Cocozzella[26], Fernando Bessone[27], Nelia Hernández[28], Cristina Alonso[1], Melina Ferreiro[2], Florencia Antinucci[3], Aldo Torre[4], Bruna D Moutinho[5], Silvia Coelho Borges[29], Fernando Gomez[7], Maria Dolores Murga[8], Federico Piñero[1], Gisela F Sotera[2], Jhonier A Ocampo[3], Valeria A Cortés Mollinedo[4], Marcos Girala[30], Pedro Montes[31], Natalia Ratusnu[32], Claudia A Zuñagua[33], Lida Castillo[34], Mauricio Castillo Barradas[35], Rocío Chávez[36], Cláudia Ivantes[37], Julia Brutti[38], Laura Tenorio[38], Jorge Garavito[39], Katherine Zevallos[40], Fernando Contreras[41], Mirtha Infante[42], Emilia Vera-Pozo[43], Martín Tagle[44], Luis G Toro[45], Carlos A De La Rocha[46], Daniela Simian[15], Marcelo O Silva[1]

[1] *Liver Unit and Liver Transplant Unit, Austral University Hospital, Pilar, Argentina*
[2] *Hepatology Section, Clinic Hospital "José de San Martín", University of Buenos Aires, Argentina*
[3] *Hepatology and Liver Transplant Unit, German Hospital, Argentina*
[4] *Gastroenterology Departmet, National Institute of Medical Sciences and Nutrition "Salvador Zubirán", México*
[5] *Gastroenterology and Hepatology Division, Clinic Hospital of University School of Medicine of São Paulo, São Paulo, Brazil*
[6] *Full Professor of Gastroenterology and Hepatology at the Federal University of Rio Grande do Sul and of Porto Alegre Clinic Hospital, Brazil*
[7] *Gastroenterology Section, El Salvador Hospital, Santiago Chile*
[8] *Gastroenterology Service, Hepatology Section, Padilla Hospital, Tucumán, Argentina*
[9] *Hepatology Section, Department of Medicine. Center for Medical Education and Clinical Research Norberto Quirno "CEMIC". Buenos Aires, Argentina*
[10] *Liver and Hepatic Transplant Unit, Universitary Hospital Favaloro Foundation, Buenos Aires, Argentina*
[11] *Fray Antonio Alcalde Civil Hospital of Guadalajara. Guadalajara, Jalisco, México*
[12] *Hepatology Section. Buenos Aires Italian Hospital, Buenos Aires, Argentina*
[13] *Universitary Hospital "Dr. José E. González,", Monterrey, México*
[14] *Hepatology Core, Prof. Edgard Santos Universitary Hospital, Federal University of Bahia, Salvador, Brazil*
[15] *Gastroenterology Section, Medicine Department, Clinical Hospital of University of Chile, Santiago, Chile*
[16] *Gastroenterology Unit, Miguel Perez Carreño Hospital, Venezuela*
[17] *Hospital Central Militar, Military School of Health Graduates, México*
[18] *Hepatology Unit, Gustavo Fricke Hospital, Viña del Mar, Chile*
[19] *Cardioinfantil Foundation, Cardiology Institute, Bogotá, Colombia*
[20] *Victor Lazarte Echegaray Hospital, Trujillo, Perú*
[21] *Department of Gastroenterology, Pontifical Catholic University of Chile, Santiago, Chile*
[22] *Gastroenterology Unit, Daniel A. Carrión National Hospital, Callao, Perú*
[23] *Gastroenterology and Transplantation Unit Foundation Santa Fe of Bogotá, Bogotá, Colombia*
[24] *Gastroenterology Service, PNP Luis N. Sáenz National Hospital, Perú*
[25] *Liver Unit, Armed Forces Hospital, Montevideo, Uruguay*
[26] *Hepatology, La Plata Italian Hospital, La Plata, Argentina*
[27] *Gastroenterology Department, Medical School, Centenario Provincial Hospital, University of Rosario School of Medicine, Rosario, Chile*
[28] *Gastroenterology Clinic, Clinic Hospital, School of Medicine, UdelaR, Montevideo, Uruguay*
[29] *Moinhos de Vento Hospital of Porto Alegre, Porto Alegre, Brasil*
[30] *Gastroenterology Department. Clinic Hospital. Faculty of Medical Sciences. Asunción National University, San Lorenzo, Paraguay*
[31] *Daniel A. Carrión National Hospital, Lima, Perú*
[32] *Hepatology Unit, Regional Hospital of Ushuaia, Ushuaia Argentina*
[33] *Liver Club, La Paz, Bolivia*
[34] *High Complexity Hospital "Virgen de la Puerta", Lima, Perú*
[35] *Hospital de Especialidades Centro Médico Nacional La Raza of the Mexican Social Security Institute, México City, México*
[36] *Adolfo Guevara Velasco National Hospital- EsSalud, Cusco, México*
[37] *Center for Surgery, Gastroenterology and Hepatology - Nossa Senhora das Graças Hospital, Curitiba, Brazil*
[38] *Liver and Liver Transplant Unit, German Hospital, Buenos Aires, Argentina*
[39] *Gastroenterology Service, Arzobispo Loayza National Hospital, Lima, Perú*
[40] *Carlos Alberto Seguín Escobedo Hospital Essalud, Arequipa, Perú*
[41] *Center for Advanced Gastroenterology, Santo Domingo, República Dominicana*
[42] *Gastroenterology Institute of Cuba*
[43] *Dr. Teodoro Maldonado Carbo Regional Hospital of IESS, Guayaquil, Ecuador*
[44] *Anglo American Clinic, Lima, Perú*
[45] *San Vicente Foundation Hospitals of Medellín and Rionegro, Colombia*
[46] *Responsible for the National Infectious Diseases Program Component: STIs/HIV/AIDS/ Viral Hepatitis, Bolivia*

Introduction and Objectives: To achieve WHO's goal of eliminating HCV, innovative strategies must be designed to diagnose and treat more patients. This study aimed to describe an implementation strategy to identify patients with HCV who were lost to follow-up (LTFU) and offer them re-linkage to Figure 1. Analysis of global DNA methylation. A) Representative dot blot using anti-5mC which recognizes global methylated DNA, anti-IgG as negative control and methylene blue staining as total DNA loading control. B) Graphs shows mean ± standard deviation of 5mC densitometry brand intensity of study groups. C) Graph that represents the percentage of global methylation of the DNA analyzed with ELISA.A one-way ANOVA statistical test and a Tukey post hoc test were performed. Group NT: only received vehicle; Group HCC: damage group induced by weekly administration of DEN and 2-AAF for 12 weeks; and Group HCC/PFD:

which received the same treatment as Group HCC, plus PFD (300 mg/kg) (**p<0.005)Figure 1. Analysis of global DNA methylation. A) Representative dot blot using anti-5mC which recognizes global methylated DNA, anti-IgG as negative control and methylene blue staining as total DNA loading control. B) Graphs shows mean ± standard deviation of 5mC densitometry brand intensity of study groups. C) Graph that represents the percentage of global methylation of the DNA analyzed with ELISA.A one-way ANOVA statistical test and a Tukey post hoc test were performed. Group NT: only received vehicle; Group HCC: damage group induced by weekly administration of DEN and 2-AAF for 12 weeks; and Group HCC/PFD: which received the same treatment as Group HCC, plus PFD (300 mg/kg) (**p<0.005)Figure 1. Analysis of global DNA methylation. A) Representative dot blot using anti-5mC which recognizes global methylated DNA, anti-IgG as negative control and methylene blue staining as total DNA loading control. B) Graphs shows mean ± standard deviation of 5mC densitometry brand intensity of study groups. C) Graph that represents the percentage of global methylation of the DNA analyzed with ELISA.A one-way ANOVA statistical test and a Tukey post hoc test were performed. Group NT: only received vehicle; Group HCC: damage group induced by weekly administration of DEN and 2-AAF for 12 weeks; and Group HCC/PFD: which received the same treatment as Group HCC, plus PFD (300 mg/kg) (**p<0.005)

Materials and Methods: We conducted an implementation study utilizing a strategy to contact patients with HCV who were not under regular follow-up in 45 centers from 13 Latin American countries. Patients with HCV were identified by the international classification of diseases (ICD-9/10) or equivalent. Medical records were then reviewed to confirm the diagnosis of chronic HCV infection defined by anti-HCV+ and detectable HCV-RNA. Identified patients who were not under follow-up by a liver specialist were contacted by telephone or email and offered a medical reevaluation.

Results: A total of 10364 patients were classified to have HCV. After reviewing their medical charts, 1349 (13%) had undetectable HCV-RNA or were wrongly coded (figure). Overall, 9015 (86.9%) individuals were identified with chronic HCV infection. A total of 5096 (56.5%) patients were under routine HCV care and 3919 (43.5%) had been LTFU. We were able to contact 1617 (41.3%) of the 3919 patients who were LTFU at the primary medical institution, of which 427 (26.4%) were cured at different institutions or were dead. Of the remaining patients, 906 (76.1%) were candidates for retrieval. Overall, patients who were LTFU were younger (58.7 vs. 61.1 years; p<0.001), were more likely to be men (57.4% vs. 49.5%; p<0.001), and to have a concomitant infection of HIV (13.8% vs. 7.3%; p<0.001) and HBV (3.1% vs. 1.7%; p<0.001).

Conclusions: In our cohort, about 1 out of 4 patients with chronic HCV who were LTFU were candidates to receive treatment. This strategy has the potential to be effective and accessible and significantly impacts the HCV care cascade. (NCT04470271)

Figure



https://doi.org/10.1016/j.aohep.2023.101053

OP-5 ALCOHOL-ASSOCIATED HEPATITIS IN LATIN AMERICA: RESULTS FROM THE AH-LATIN STUDY

Luis Antonio Díaz[1], Jorge Arnold[1], Francisco Idalsoaga[1], Gustavo Ayares[1], María Ayala-Valverde[2], Diego Perez[2], Jaime Gomez[2], Rodrigo Escarate[2], Juan Pablo Roblero[3], Blanca Norero[4], José Antonio Velarde[5], Janett Jacobo[6], Jesús Varela[7], Scherezada Mejía Loza[8], Jacqueline Córdova[8], Rita Silva[9], Cristina Melo Rocha[10], Roberta C. Araujo[11], Gustavo Henrique Pereira[12], Claudia Couto[13], Fernando Bessone[14], Mario Tanno[14], Gustavo Romero[15], Manuel Mendizabal[16], Sebastián Marciano[17], Melisa Dirchwolf[18], Pedro Montes[19], Patricia Guerra Salazar[20], Geraldine Ramos[20], Juan Carlos Restrepo[21], Gabriel Díaz[22], Luis Guillermo Toro[23], Enrique Carrera[24], Brahmania Mayur[25], Singal Ashwani[26], Bataller Ramon[27], Shah Vijay[28], Kamath Patrick S.[28], Marco Arrese[1], Juan Pablo Arab[1,25,28,29,30]

[1] *Department of Gastroenterology, Pontifical Catholic University of Chile, Santiago, Chile*
[2] *El Pino Hospital, Santiago, Chile*
[3] *Gastroenterology Section, Clinic Hospital of University of Chile, Medical School of University of Chile, Santiago, Chile*
[4] *Sótero del Río Hospital, Santiago, Chile*
[5] *Civil Hospital of Guadalajara, Guadalajara, México*
[6] *General Manuel Gea González Hospital, Ciudad De México, México*
[7] *Dublán Hospital, Chihuahua, México*
[8] *Juárez Hospital of Mexico, Mexico City, Mexico*
[9] *Liver Transplantation Unit and the Base Hospital of the São Jose of Rio Preto Medical School, Sao Paulo, Brasil*
[10] *Fhaj Foundation Hospital Adriano Jorge, Amazonas, Brasil*
[11] *Clinic Hospital of Medical School of Ribeirão Preto, Ribeirão Preto, Brasil*
[12] *Bonsucesso Federal Hospital, Rio de Janeiro, Brasil*
[13] *Clinic Hospital of Federal University of Minas Gerais, Belo Horizonte, Brasil*
[14] *Centenario Provincial Hospital, Santa Fe, Argentina*
[15] *Gastroenterology Hospital " Dr. Carlos Bonorino Udaondo", Buenos Aires, Argentina*
[16] *Austral University Hospital, Pilar, Argentina*
[17] *Buenos Aires Italian Hospital, Buenos Aires, Argentina*
[18] *Rosario Private Hospital, Rosario, Argentina*
[19] *Daniel Alcides Carrión National Hospital - Callao, Bellavista, Perú*
[20] *Bolivian-Japanese Gastroenterological Institute, Cochabamba, Bolivia*
[21] *Pablo Tobon Uribe Hospital. Antioquia University, Medellín, Colombia*
[22] *Valle De Lili Foundation, Cali, Colombia*
[23] *San Vicente Hospital, Foundation Rionegro, Antioquía, Colombia*
[24] *Eugenio Espejo Specialty Hospital, Quito, Ecuador*
[25] *Department of Medicine, Division of Gastroenterology, Western University, London Health Sciences Center, London, Ontario, Canada*